Darmiyan, Inc. Announces Launch of Groundbreaking BrainSee Platform for Alzheimer’s Testing

Darmiyan, Inc., a pioneer in brain technology, is proud to announce the launch of the BrainSee Platform, integrating the first-of-its-kind FDA-approved BrainSee Test for Alzheimer’s disease. This innovative platform is designed to revolutionize how individuals with memory concerns assess and monitor their risk of progression to Alzheimer’s dementia within the next five years. The BrainSee Test, a cornerstone of the BrainSee Platform, departs from traditional Alzheimer’s assessments that rely on non-specific biomarkers such as Amyloid or Tau. The test is fully non-invasive and highly accurate and works by proposing amnestic mild cognitive impairment (a type of cognitive impairment where memory loss is the predominant symptom). It utilizes advanced AI algorithms to analyze routine clinical brain MRIs and cognitive test results, providing a numerical score between 0 and 100 to indicate a patient’s risk level of progression to Alzheimer’s dementia within five years.